The Documentation About "Codex Alimentarius"

Suppression of Use of Vitamins Against Common Disorders
-- Hypercholesterolemia

The Codex Alimentarius scheme of the pharmaceutical cartel, if successful, will prohibit dissemination of information linking vitamin deficiencies and the elevation of risk-bearing substances in blood (e.g. cholesterol, triglycerides, and homocysteine).

If the pharmaceutical cartel has its way, a diagnosis of "high blood lipids" or "high cholesterol" or "high triglycerides," or other common conditions, will permanently alter the way a person lives. These prescriptions will become a function of every day life. For the pharmaceutical companies, these widespread metabolic disorders are viewed hungrily as multi-billion-dollar opportunities for the sales of cholesterol-reducing drugs, and other synthetics, which patients will buy in increasing quantities, regardless of price.

At the same time, through its influence on medical schools, the pharmaceutical cartel is continually lobbying for lower acceptable levels of blood cholesterol. The current limit of 200 mg/dL is defined as "unhealthy" for more than half of mankind; the only impetus for this is to force the sales of cholesterol-reducing drugs.

Thus it is unsurprising that worldwide, annual sales of cholesterol-reducing drugs exceeded ten billion D. Marks.

All currently marketed cholesterol-reducing drugs are carcinogenic -- which the pharmaceutical industry welcomes-- because the ensuing disease means more business for the "disease industry."

An optimal vitamin regimen not only stabilizes arterial walls but also stabilizes blood lipids and other risk factors in the blood. The plan to use Codex Alimentarius to prohibit dissemination of this vital information violates human rights.

The American Physicians' Journal of Jan 6, 1996 warned:
"All currently prescribed cholesterol-reducing drugs are carcinogenic."
Thus far, the pharmaceutical companies have suppressed this warning to physicians.